Algodon Wine Estates

Hotel Reservations

Trellis Bioscience Names Bruce Keyt, Ph.D. as Chief Technology Officer and Vice President of Research

Source: Trellis Bioscience

SOUTH SAN FRANCISCO, CA (April 10, 2007): Trellis Bioscience Inc., a privately held biotechnology company, today announced the appointment of Bruce A. Keyt, Ph.D. as Chief Technology Officer and Vice President of Research. Dr. Keyt is a biotechnology industry veteran having more than 24 years scientific and management experience, including senior scientific and management positions at Abgenix, Millennium Pharmaceuticals and Genentech.

"Bruce Keyt's long history within the biotechnology industry includes extensive background in many phases of drug development, including R&D work on six major projects that have resulted in marketed therapeutics," said Brian Cunningham, Chief Executive Officer of Trellis Bioscience. "His outstanding expertise in the preclinical development, protein chemistry and pharmacology of therapeutic antibody products will serve Trellis well as we advance our human antibody programs toward the clinic, in the areas of infectious disease and oncology."

As Vice President, Preclinical Development at Abgenix, Dr. Keyt led the efforts on the development of more than 20 therapeutics candidates in the field of cancer and inflammation, resulting in the filing of two INDs. Prior to that, he held senior management positions for four years at Millennium Pharmaceuticals, where as Director of Biotherapeutics Oncology, he led the group validating targets and developing model systems for preclinical candidates. He began his professional career with a 16-year tenure at Genentech, where his efforts included work on six programs that have resulted in marketed drugs, including therapeutic antibodies Avastin and Lucentis. Dr. Keyt is the co-inventor on 12 granted US patents and author of over 50 scientific publications. He holds a Ph.D. degree in biochemistry and pharmacology from Tufts University School of Medicine.

Important Notes:

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This press release may contain certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Algodon Wines & Luxury Development Group (Algodon Partners) and its respective subsidiaries ("the Company") estimated or anticipated future results or other non-historical facts are forward-looking and reflect the Company's current perspective of existing trends and information. These statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date set forth above. The Company undertakes no obligation to update publicly any forward-looking statement, whether because of new information, future events or otherwise.

Media/Analyst Contact:
Algodon Group
Eric Stear

External Link:

Reservations +54 (11) 3530 7777Click here for suite availability & hotel reservations Special PromotionsExciting packages at Algodon Mansion Contact UsSuite rate monthly specials. Newsletter sign-up.
Print Email
More Algodon Properties